| Mrs Misty Coggins Handy, CRNA | |
|
110 29th Ave N, Ste 202, Nashville, TN 37203-1401 | |
| (615) 327-4304 | |
| Not Available |
| Full Name | Mrs Misty Coggins Handy |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 22 Years |
| Location | 110 29th Ave N, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003815978 | NPI | - | NPPES |
| 009912325 | Medicaid | AL | |
| 4049479 | Other | TN | BCBS NUMBER |
| 74005448 | Medicaid | KY | |
| 3631788 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 055130 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tristar Skyline Medical Center | Nashville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Medical Group, P.c. | 6901702307 | 469 |
News Archive
General practitioners would be crucial in avoiding large numbers of deaths in Australia as a result of a pandemic influenza outbreak, researchers at The Australian National University have shown.
TissueGene, Inc. today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed brand name Invossa for TissueGene-C, the Company's proprietary product in development for treatment of osteoarthritis of the knee. FDA's acceptance of the proprietary brand name is subject to the Agency's final determination prior to any approval of the product's Biologic License Application (BLA) and market launch.
Adis, a leading global provider of drug information, has taken a major step forward in its quest to make expertly written drug information more accessible, with the launch of a new platform AdisInsight. The platform presents a unique, joined-up view of current evidence on drug treatments being developed worldwide - how well they work, how safe they are, who is working on them, and how soon they will be available - in a single database.
Warner Chilcott plc today announced that its subsidiary Warner Chilcott Corporation (the "Company") has received and accepted for purchase approximately $290.5 million aggregate principal amount of its 8-3/4% Senior Subordinated Notes due 2015 (Cusip No. 93443MAC5) (the "Notes") validly tendered by 11:59 p.m., New York City time, on Tuesday, December 29, 2009, (the "Consent Date"), and has received consents from holders of approximately 76% of the Notes as of the Consent Date.
A research case report describing lung injury related to e-cigarette use in a 17-year-old Canadian may be the first documented case of a new form of damage from vaping products.
› Verified 1 days ago
| Entity Name | Anesthesia Medical Group, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215932413 PECOS PAC ID: 6901702307 Enrollment ID: O20031208000822 |
News Archive
General practitioners would be crucial in avoiding large numbers of deaths in Australia as a result of a pandemic influenza outbreak, researchers at The Australian National University have shown.
TissueGene, Inc. today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed brand name Invossa for TissueGene-C, the Company's proprietary product in development for treatment of osteoarthritis of the knee. FDA's acceptance of the proprietary brand name is subject to the Agency's final determination prior to any approval of the product's Biologic License Application (BLA) and market launch.
Adis, a leading global provider of drug information, has taken a major step forward in its quest to make expertly written drug information more accessible, with the launch of a new platform AdisInsight. The platform presents a unique, joined-up view of current evidence on drug treatments being developed worldwide - how well they work, how safe they are, who is working on them, and how soon they will be available - in a single database.
Warner Chilcott plc today announced that its subsidiary Warner Chilcott Corporation (the "Company") has received and accepted for purchase approximately $290.5 million aggregate principal amount of its 8-3/4% Senior Subordinated Notes due 2015 (Cusip No. 93443MAC5) (the "Notes") validly tendered by 11:59 p.m., New York City time, on Tuesday, December 29, 2009, (the "Consent Date"), and has received consents from holders of approximately 76% of the Notes as of the Consent Date.
A research case report describing lung injury related to e-cigarette use in a 17-year-old Canadian may be the first documented case of a new form of damage from vaping products.
› Verified 1 days ago
| Entity Name | Stage Two Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063709392 PECOS PAC ID: 8022286699 Enrollment ID: O20110726000522 |
News Archive
General practitioners would be crucial in avoiding large numbers of deaths in Australia as a result of a pandemic influenza outbreak, researchers at The Australian National University have shown.
TissueGene, Inc. today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed brand name Invossa for TissueGene-C, the Company's proprietary product in development for treatment of osteoarthritis of the knee. FDA's acceptance of the proprietary brand name is subject to the Agency's final determination prior to any approval of the product's Biologic License Application (BLA) and market launch.
Adis, a leading global provider of drug information, has taken a major step forward in its quest to make expertly written drug information more accessible, with the launch of a new platform AdisInsight. The platform presents a unique, joined-up view of current evidence on drug treatments being developed worldwide - how well they work, how safe they are, who is working on them, and how soon they will be available - in a single database.
Warner Chilcott plc today announced that its subsidiary Warner Chilcott Corporation (the "Company") has received and accepted for purchase approximately $290.5 million aggregate principal amount of its 8-3/4% Senior Subordinated Notes due 2015 (Cusip No. 93443MAC5) (the "Notes") validly tendered by 11:59 p.m., New York City time, on Tuesday, December 29, 2009, (the "Consent Date"), and has received consents from holders of approximately 76% of the Notes as of the Consent Date.
A research case report describing lung injury related to e-cigarette use in a 17-year-old Canadian may be the first documented case of a new form of damage from vaping products.
› Verified 1 days ago
| Entity Name | Eye Center Of Nashville Uap, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538567375 PECOS PAC ID: 1052638996 Enrollment ID: O20150402000990 |
News Archive
General practitioners would be crucial in avoiding large numbers of deaths in Australia as a result of a pandemic influenza outbreak, researchers at The Australian National University have shown.
TissueGene, Inc. today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed brand name Invossa for TissueGene-C, the Company's proprietary product in development for treatment of osteoarthritis of the knee. FDA's acceptance of the proprietary brand name is subject to the Agency's final determination prior to any approval of the product's Biologic License Application (BLA) and market launch.
Adis, a leading global provider of drug information, has taken a major step forward in its quest to make expertly written drug information more accessible, with the launch of a new platform AdisInsight. The platform presents a unique, joined-up view of current evidence on drug treatments being developed worldwide - how well they work, how safe they are, who is working on them, and how soon they will be available - in a single database.
Warner Chilcott plc today announced that its subsidiary Warner Chilcott Corporation (the "Company") has received and accepted for purchase approximately $290.5 million aggregate principal amount of its 8-3/4% Senior Subordinated Notes due 2015 (Cusip No. 93443MAC5) (the "Notes") validly tendered by 11:59 p.m., New York City time, on Tuesday, December 29, 2009, (the "Consent Date"), and has received consents from holders of approximately 76% of the Notes as of the Consent Date.
A research case report describing lung injury related to e-cigarette use in a 17-year-old Canadian may be the first documented case of a new form of damage from vaping products.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Misty Coggins Handy, CRNA 110 29th Ave N, Ste 202, Nashville, TN 37203-1401 Ph: (615) 327-4304 | Mrs Misty Coggins Handy, CRNA 110 29th Ave N, Ste 202, Nashville, TN 37203-1401 Ph: (615) 327-4304 |
News Archive
General practitioners would be crucial in avoiding large numbers of deaths in Australia as a result of a pandemic influenza outbreak, researchers at The Australian National University have shown.
TissueGene, Inc. today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed brand name Invossa for TissueGene-C, the Company's proprietary product in development for treatment of osteoarthritis of the knee. FDA's acceptance of the proprietary brand name is subject to the Agency's final determination prior to any approval of the product's Biologic License Application (BLA) and market launch.
Adis, a leading global provider of drug information, has taken a major step forward in its quest to make expertly written drug information more accessible, with the launch of a new platform AdisInsight. The platform presents a unique, joined-up view of current evidence on drug treatments being developed worldwide - how well they work, how safe they are, who is working on them, and how soon they will be available - in a single database.
Warner Chilcott plc today announced that its subsidiary Warner Chilcott Corporation (the "Company") has received and accepted for purchase approximately $290.5 million aggregate principal amount of its 8-3/4% Senior Subordinated Notes due 2015 (Cusip No. 93443MAC5) (the "Notes") validly tendered by 11:59 p.m., New York City time, on Tuesday, December 29, 2009, (the "Consent Date"), and has received consents from holders of approximately 76% of the Notes as of the Consent Date.
A research case report describing lung injury related to e-cigarette use in a 17-year-old Canadian may be the first documented case of a new form of damage from vaping products.
› Verified 1 days ago
Amanda B Dickert I, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1215 21st Ave S, Nashville, TN 37232 Phone: 615-343-6336 Fax: 615-343-1966 | |
Charles Ryan Swafford, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4230 Harding Pike, Suite 435, Nashville, TN 37205 Phone: 615-385-3704 Fax: 615-292-1321 | |
Jana Koehn, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4 Academy Pl Apt 307, Nashville, TN 37210 Phone: 316-243-7921 | |
Jon Schwindt, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 110 29th Ave N, Ste 202, Nashville, TN 37203 Phone: 615-327-4304 | |
Joshua Lemay, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 110 29th Ave N, Suite 202, Nashville, TN 37203 Phone: 615-327-4304 Fax: 615-327-7940 | |
Jonathan Keith Allgood, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4230 Harding Pike, Suite 435, Nashville, TN 37205 Phone: 615-385-3704 Fax: 615-292-1321 |